Salvatore Siena Selected Research

Cetuximab (Erbitux)

1/2021	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer.
12/2020	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
3/2020	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer.
1/2018	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.
1/2018	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
12/2016	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
6/2016	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
2/2016	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
11/2015	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
10/2015	The genomic landscape of response to EGFR blockade in colorectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Salvatore Siena Research Topics

Disease

118	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 07/2004
105	Neoplasms (Cancer) 10/2022 - 05/2002
21	Disease Progression 01/2021 - 05/2002
19	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2005
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 05/2009
6	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2003
5	Circulating Neoplastic Cells 05/2021 - 02/2014
5	Fatigue 01/2020 - 08/2002
5	Exanthema (Rash) 06/2016 - 05/2005
4	Sarcoma (Soft Tissue Sarcoma) 10/2020 - 03/2007
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 05/2002
4	Anemia 03/2009 - 08/2002
3	Stomach Neoplasms (Stomach Cancer) 01/2021 - 11/2019
3	Adenocarcinoma 01/2021 - 02/2014
3	Melanoma (Melanoma, Malignant) 01/2021 - 01/2017
3	Colonic Neoplasms (Colon Cancer) 01/2019 - 05/2008
3	Lung Neoplasms (Lung Cancer) 01/2018 - 08/2002
3	Pancreatic Neoplasms (Pancreatic Cancer) 02/2015 - 01/2008
3	Iron Deficiencies 03/2009 - 01/2008
3	Neutropenia 12/2006 - 05/2003
2	Carcinogenesis 06/2020 - 03/2014
2	Rectal Neoplasms (Rectal Cancer) 01/2020 - 09/2019
2	Ovarian Neoplasms (Ovarian Cancer) 12/2016 - 01/2012
2	Pain (Aches) 04/2016 - 12/2012
2	Alopecia (Baldness) 07/2014 - 12/2012
2	Chronic Renal Insufficiency 03/2009 - 01/2008
2	Medulloblastoma 11/2008 - 06/2005
2	Febrile Neutropenia 10/2003 - 05/2003

Drug/Important Bio-Agent (IBA)

38	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2003
37	Panitumumab (Vectibix)FDA Link 01/2020 - 05/2005
32	Cetuximab (Erbitux)FDA Link 01/2021 - 07/2004
27	Monoclonal AntibodiesIBA 01/2022 - 05/2005
16	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2009
11	entrectinibIBA 10/2022 - 12/2015
11	Pharmaceutical PreparationsIBA 01/2021 - 08/2009
10	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2022 - 11/2010
10	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2011
9	Phosphotransferases (Kinase)IBA 01/2022 - 06/2013
8	Circulating Tumor DNAIBA 05/2021 - 02/2014
8	regorafenibIBA 06/2020 - 01/2013
7	DNA (Deoxyribonucleic Acid)IBA 05/2021 - 04/2008
7	Trastuzumab (Herceptin)FDA Link 01/2021 - 11/2015
7	Gemcitabine FDA Link 02/2016 - 07/2007
6	AntibodiesIBA 01/2022 - 08/2010
6	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 07/2007
6	Lapatinib (GW572016)FDA Link 01/2021 - 11/2015
6	Cell-Free Nucleic AcidsIBA 01/2021 - 08/2015
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2020 - 06/2012
5	Calcibiotic Root Canal SealerIBA 12/2016 - 02/2014
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
4	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2020
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2020
4	Biological ProductsIBA 01/2020 - 12/2010
4	Irinotecan (Camptosar)FDA LinkGeneric 12/2016 - 07/2004
4	IronIBA 03/2009 - 11/2004
3	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 12/2010
3	trastuzumab deruxtecanIBA 01/2021 - 01/2020
3	pertuzumabIBA 01/2021 - 01/2020
3	Anaplastic Lymphoma KinaseIBA 11/2020 - 10/2014
3	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 11/2010
3	Codon (Codons)IBA 06/2016 - 10/2010
3	Sorafenib (BAY 43-9006)FDA Link 07/2014 - 08/2009
3	Growth Factor ReceptorsIBA 03/2014 - 05/2005
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2012 - 05/2009
3	Hemoglobins (Hemoglobin)IBA 04/2008 - 08/2002
3	Filgrastim (Neupogen)FDA Link 12/2006 - 05/2003
3	pegfilgrastim (Neulasta)FDA Link 12/2006 - 05/2003
3	AntigensIBA 12/2005 - 05/2004
2	pembrolizumabIBA 10/2022 - 01/2022
2	VaccinesIBA 01/2022 - 10/2005
2	TropomyosinIBA 01/2022 - 01/2016
2	tyrosine receptor (receptor, tyrosine)IBA 10/2021 - 01/2016
2	encorafenibIBA 01/2021 - 10/2020
2	human ERBB2 proteinIBA 01/2021 - 01/2018
2	Protein Kinases (Protein Kinase)IBA 06/2020 - 03/2014
2	dabrafenibIBA 01/2020 - 01/2018
2	trametinibIBA 01/2020 - 01/2018
2	Dacarbazine (DIC)FDA LinkGeneric 01/2017 - 04/2013
2	Lenalidomide (CC 5013)FDA Link 01/2013 - 01/2013
2	Zoledronic Acid (Zometa)FDA Link 12/2012 - 11/2012
2	Denosumab FDA Link 12/2012 - 11/2012
2	HematinicsIBA 04/2008 - 01/2008
2	Neoplasm Antigens (Tumor Antigens)IBA 10/2005 - 05/2004
2	CytokinesIBA 10/2005 - 10/2003
2	Darbepoetin alfa (Aranesp)FDA Link 10/2003 - 08/2002
1	dostarlimabIBA 10/2022
1	larotrectinibIBA 10/2022
1	disitamab vedotinIBA 03/2022
1	trastuzumab duocarmazineIBA 03/2022

Therapy/Procedure

75	Therapeutics 10/2022 - 08/2002
38	Drug Therapy (Chemotherapy) 01/2022 - 08/2002
7	Immunotherapy 01/2022 - 11/2005
4	Stem Cell Transplantation 10/2020 - 05/2002
3	Retreatment 02/2022 - 02/2019
3	Radiotherapy 02/2021 - 11/2008
3	Precision Medicine 01/2021 - 11/2011
3	Transplantation 10/2020 - 05/2002
3	Injections 12/2006 - 05/2003
2	Aftercare (After-Treatment) 04/2016 - 05/2005